| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib is a farnesyltransferase inhibitor (FTI) that blocks the farnesylation of H-ras and other Ras proteins. This modification is essential for their proper functioning, and by inhibiting it, Tipifarnib disrupts Ras signaling pathways, potentially leading to antitumor effects. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
Lonafarnib is a farnesyltransferase inhibitor that has shown promise in inhibiting H-ras and other Ras proteins. It has been investigated for its potential anticancer effects, particularly in certain types of tumors that are driven by Ras mutations. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A is an antibiotic that also inhibits farnesyltransferase. As a result, it can disrupt the proper localization and activity of H-ras and other Ras proteins, potentially impacting tumor growth and proliferation. | ||||||
2-hydroxybenzaldehyde semicarbazone | 3030-97-5 | sc-274882 | 1 g | $524.00 | ||
This compound is known to inhibit H-ras prenylation and could potentially be explored as an anticancer agent by disrupting Ras signaling. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $32.00 $86.00 $150.00 | 3 | |
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that has been investigated for its potential inhibitory effects on H-ras. It may act by interfering with Ras signaling pathways, but its exact mechanism of action is not fully understood. | ||||||